Heart Failure

Cath Lab Digest explores the role of Heart Failure in the treatment of coranary artery disease. For more information, feel free to browse through some of articles below on the topic of Heart Failure.

New Developments in Congestive Heart Failure: The Use of Ultrafiltration The System 100 Fluid Removal System is a mechanical pump and ultrafiltration system engineered to simply, safely and precisely remove excess fluid (primarily excess water) from fluid-overloaded patients.

Clinical and Industry News ? The project is made possible by reverse engineering. After treatment, patients?

Clinical and Industry News Medical Ventures Signs Letter of Intent to Acquire Angiometrx; Homocysteine Tied to Heart Failure; Cardiogenesis Granted FDA Panel Review of Percutaneous Myocardial Revascularization (PMR) System; AXIOM Artis TA Now with Integrated Ultrasound; Vascular Access Safety Kit; EECP Demonstrated to be Effective in Patients with Cardiac Syndrome X; Teen Gets Piercing-Related Heart Infection; In Case of Heart Failure, Mice Don?t Act Like Men; Demographic Changes Direct the Growth of Interventional Cardiology Markets; Argatroban Assigned Medicare and Medicaid Ambulatory Payment Classification Code; CryoCor Clinical Progress Update; Medtronic Study of Neurostimulation for Refractory Angina Pain Gets Underway; Healthcare Institutions Can Take Positive Steps to Ease Critical U.S. Nursing Shortage

Clinical and Industry News for April 2007 The minimally invasive placement of the device will allow the transformation of the treatment of chronic heart failure patients from the acute decompensated hospitalized patient to the chronic, ambulatory heart failure patient. Mobile Aspects can be found on the web at www.mobileaspects.com. Boston Scientific Announces Program to Improve Anti-Platelet Compliance for DES Patients Boston Scientific Corporation announced a program designed to improve patient compliance with physician-prescribed...

Clinical and Industry News ACE Inhibitors May Reduce Death, Heart Attack and Stroke in Patients with Coronary Artery Disease Angiotension-converting enzyme (ACE) inhibitors may reduce cardiovascular risk and the risk of death in patients with coronary artery disease, according to a new analysis of previously conducted clinical trials reported in the Archives of Internal Medicine. These results, along with those previously reported in patients who have coronary artery disease with left ventricular dysfunction or heart ...

Product and Industry News The 60-mm device is ideally suited to treat long, diffuse in-stent restenosis. ? Abbott currently markets Biocompatibles?

News from the American Heart Association Scientific Sessions (AHA) Held November 7-10, 2004 in New Orleans, Louisianna

Clinical and Industry News FDA Approves Cordis? CYPHER Sirolimus-eluting Coronary Stent; St. Jude Medical Announces FDA Approval of Isoflex S Lead and First Implant of Isoflex P Lead, New Bradycardia Pacing Leads; FDA Panel Unanimously Approves Cook?s Zenith® AAA Endovascular Graft; Study Shows that Cardiac Resynchronization Therapy Reverses Progression of Heart Failure; CardioNow Expands its Cardiac Imaging Archiving & Sharing Capabilities & Addresses HIPAA Security Issues with Latest Software Release; GE Medical Systems? Electron Beam Tomography Exam is Leading Predictor of Heart Attack and Death; Approval and First Implants of the QuickSite Left Heart Pacing Lead; Preclinical Study of Stents for Treatment of Vulnerable Plaque; Study Evaluates Therapeutic Options for Preventing Heart Attacks; Duke Children?s Hospital and Health Center Selects Camtronics' Image and Information Management Solution for Pediatric Cardiology; New, Less Invasive Coronary Artery Bypass Procedure Performed Live for Surgeons at Miami Conference; GE, Ford, UPS, P&G, Verizon, Others Back Bridges to Excellence, a New Pay-for-Quality Initiative For Physicians; Latest Market Report on U.S. Cath Lab Facilities Shows Continued Growth in Cath Lab Case Volume; Part of Genetic Tie to Heart Disease Explained; Medtronic Sees New Stent on Market by ?05

Clinical and Industry News Clinical and Industry News Industry News: Clinical and Industry News - Lifestyle Changes Can Quickly Reverse Heart Risks In less than a month, individuals can reverse serious heart disease risk factors by making significant lifestyle changes, researchers are reporting. Amiodarone plus beta-blocker significantly reduced (73 percent) the risk of shock compared with beta-blocker alone and sotalol (57 percent reduction). The researchers found that sibling CVD was associated with a 55 percent ...

Florida?s First Experience with a Targeted Renal Therapy Infusion System The Osceola Regional Medical Center?s first experience with targeted renal therapy (TRT) utilizing the Benephit? Infusion System (FlowMedica, Inc., Fremont, CA) occurred on June 22, 2005. This new device is intended as a selective infusion catheter system. It delivers therapeutic agents directly to the renal arteries through a dedicated infusion catheter while allowing simultaneous coronary procedures through a single vessel access site. Since our center?s initial experience in June 2005, fourteen patients with acute renal insufficiency in need of diagnostic cardiac catheterization have successfully received targeted renal therapy (TRT) with the Benephit Infusion System at Osceola Regional Medical Center. Several of these patients had subsequent percutaneous transluminal coronary angioplasty via the infusion system. This new device is intended to help prevent further kidney dysfunction in patients undergoing coronary or peripheral procedures.1